Psoriasis

Boni Elewski, MD, reviews a case of a woman in the emergency department with a severe GPP flare.

Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.

Boni Elewski, MD, shares her personal experience using generalized pustular psoriasis treatments in the clinical setting.

Drs Raj Chovatiya and Boni Elewski discuss a patient case and the challenges of diagnosing generalized pustular psoriasis (GPP), commenting on the many types of psoriasis and treatment.

FDA action is no longer expected in Q3 of 2023.

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.

There may be delays in diagnosis and treatment of psoriasis in patients with darker skin tones due to the clinical presentation variations and less visible erythema.

Specific dermoscopic features help determine a diagnosis and the severity of disease.

Mona Shahriari, MD, introduces "Psoriasis Gaps in Care," a special section of the Dermatology Times September print issue dedicated to skin of color research in psoriasis.

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis provides an opportunity for clinicians to share knowledge and research.

Websites and educational materials are available to support clinicians in treating their patients with skin of color.

Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.

Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, define what differentiates generalized pustular psoriasis (GPP) from other forms of psoriasis and discuss tools for diagnosing GPP.

Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors.

Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Apremilast treatment for psoriasis and psoriatic arthritis can be managed effectively through telehealth visits.

In the cohort trial, 85% of patients showed an improvement of more than 50 on PASI.

Click here to answer this week’s poll.

Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.

Erin Boh, MD, discusses the role of steroid administration and withdrawal as a trigger for GPP, highlighting the importance of physician awareness of external influences initiating this condition.

The findings highlight new data on AXL expression in inflammatory diseases.